The focus of this project is characterize signal transduction pathways downstream of K-Ras that mediate the pathogenesis of pancreatic ductal adenocarcinoma (PDAC). Our working hypothesis is that K-Rasdependent activation of phosphoinositide 3-kinase (PI3K) plays a critical role in this cancer. We speculate that pathways downstream of PI3K play diverse biological roles at every step along the PDAC progression process?specifically effecting rapid cell proliferation, resistance to apoptosis, aggressive motogenic behavior and angiogenesis. Further we propose that the detailed identification of both the upstream and downstream components of this signaling network would provide information on critical targets for improved therapeutics. The activation state of components of the Ras/PI3K/Akt signaling pathway will be assessed in the various mouse models for multistage PDAC being developed in Project 1. These models include expression of mutant K-Ras in the pancreas in the context of germline loss of various tumor suppressor genes (INK4a/Arf, p53;and/or SMAD4). Phospho-specific antibodies will be utilized in western blots, tissue staining and cytoimmunoflourescence to define the activation state of protein kinases downstream of Ras, including ERK, AKT, tuberin, FOXO family members, p70S6K, S6 and 4EBP1 as a function of tumor progression in the mouse models that are generated and phenotypically characterized in Projects 1 and 4. In addition these same components will be evaluated in human tissues and cell lines available from the Biobank Core. The activation of these pathways will be compared to the genetic profiles determined in Project 1 in order correlate genomic perturbations with biochemical responses. A strong emphasis will be placed on how these activation events relate to increasing grades of PanIN and the tumor biological properties of advanced PDAC tumors including angiogenesis in collaboration with Project 3. This same analysis will be used to characterize the properties of potential PDAC cancer stem cells defined in Project 4. In addition, the requirement for PI3K signaling components for tumorigenic growth in human PDAC cell lines will be evaluated using inducible shRNA vectors. Finally, a rigorous genetic approach to assess the functional role of PI3K signaling in PDAC pathogenesis will be undertaken by crossing mice that are conditionally deficient in PI3K subunits to the aforementioned mouse models. The identification of the crucial mediators of K-Ras-dependent tumorigenesis across the well-defined tumor contexts will illuminate future drug targets and pinpoint the critical molecules underpinning the biological progression of this deadly disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA117969-04
Application #
7754677
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
4
Fiscal Year
2009
Total Cost
$380,488
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Biancur, Douglas E; Kimmelman, Alec C (2018) The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870:67-75
Chen, Yang; LeBleu, Valerie S; Carstens, Julienne L et al. (2018) Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. EMBO Mol Med 10:
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451
Mendt, Mayela; Kamerkar, Sushrut; Sugimoto, Hikaru et al. (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3:
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Anglin, Justin; Zavareh, Reza Beheshti; Sander, Philipp N et al. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 28:2675-2678
Yang, Annan; Herter-Sprie, Grit; Zhang, Haikuo et al. (2018) Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov 8:276-287
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945

Showing the most recent 10 out of 134 publications